Immatics N.v. · NASDAQ:IMTX
Immatics — Investor Presentation (October 2024)
80 slides from Immatics's investor presentation, Oct 10, 2024
Slide 1: Immatics Corporate Presentation
Delivering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation October 10, 2024
Slide 2: Forward-Looking Statement
Forward - Looking Statement This presentation (“Presentation”) is provided by Immatics N . V . (“Immatics” or the “Company”) for informational purposes only . The information contained herein does not purport to be all - inclusive and none of Immatics, any of its affiliates, any of its or their resp
Slide 3: Building a Leading TCR Therapeutics Company
Therapeutic Op p o rt u n ity Potential for addressing large patient populations with high prevalence targets in solid tumors Two Clinical - Stage Modalities Pipeline of TCR - T and TCR Bispecific product candidates in clinical & preclinical development Building a Leading TCR Therapeutics Company 3
Slide 4: 2H2024 Catalysts for ACTengine and TCER Clinical Lead Assets
2H2024 Catalysts for ACTengine® and TCER® Clinical Lead Assets Projected Cash Runway into 2027 to Reach Multiple Value Inflections Points 4 • Targeted randomized Phase 3 trial 1 for ACTengine® IMA203 in 2L+ melanoma in 2024 • Clinical data update from Phase 1b dose expansion trial at SMR Conference
Slide 5: Two Distinct TCR-based Therapeutic Modalities in Clinical Development
Two Distinct TCR - based Therapeutic Modalities in Clinical Development 5 Differentiated positioning of ACTengine® vs. TCER® based on patient population and medical need I n t r o 1 Interim data update from the ACTengine® IMA203 (published Oct 10, 2024) and IMA203CD8 monotherapies (published Novembe
Slide 6: Our Pipeline of TCR-based Adoptive Cell Therapies and Bispecifics
Our Pipeline of TCR - based Adoptive Cell Therapies and Bispecifics 6 I n t r o 1 Phase 1a: Dose escalation, Phase 1b: Dose expansion; 2 Immatics’ proprietary ACTallo® platform utilizing Editas’ CRISPR gene editing technology; 3 mRNA - enabled in vivo expressed TCER® molecules Phase 3 Phase 2 Phase
Slide 7: Realizing the Full Multi-Cancer Opportunity of PRAME
Realizing the Full Multi - Cancer Opportunity of PRAME ACTengine® IMA203 (TCR - T) and TCER® IMA402 (TCR Bispecific) 7 A C T en g i ne® IMA203 (TCR - T) Cancer Cell Death PRAME is one of the most promising and most prevalent, clinically validated solid tumor targets known to date Leverage the full p
Slide 8: ACTengine IMA203 – TCR-T Targeting PRAME
ACTengine® IMA203 – TCR - T Targeting PRAME 8
Slide 9: The Multi-Cancer Opportunity of PRAME
The Multi - Cancer Opportunity of PRAME One of the Most Promising Solid Tumor Targets for TCR - based Therapies Known To Date 9 High prevalence High target density Homogeneous expression “Clean” expression profile Clinical proof - of - concept s qNSC L C Ovarian Cancer PRAME fulfills all properties
Slide 10: IMA203 TCR-T Has the Potential to Reach a Large Patient Population
Patient Population PRAME Positive R/R Incidence Incidence Selected Indications Based on R/R Incidence; PRAME and HLA - A*02:01+ 2,999 95% 7,700 99,800 Cut. Melanoma 292 89% 800 1,500 Uveal Melanoma 4,408 84% 12,800 19,900 Ovarian Carcinoma 4,255 97% 10,700 62,700 Uterine Carcinoma 779 100% 1,900 3,3
Slide 11: ACTengine IMA203 Targeting PRAME – Mechanism of Action
ACTengine® IMA203 Targeting PRAME – Mechanism of Action Immatics’ a ing - T Approach 11 I MA2 0 3 LEUKAPHARESIS
Slide 12: ACTengine IMA203 TCR-T Product Manufacturing
ACTengine® IMA203 TCR - T Product Manufacturing Differentiated Manufacturing Process and Setup 1 - week manufacturing process followed by 1 - week QC release testing High manufacturing success rate of >95% to reach IMA203 targ t os Lean and cost - efficient process Proprietary Manufacturing Process
Slide 13: ACTengine IMA203 TCR-T Monotherapy – Patient Flow
ACTengine® IMA203 TCR - T Monotherapy – Patient Flow HLA - A*02 Testing Blood sample; Central lab Treatment & Observation Phase Long Term Follow - up Screening & Manufacturing Phase Manufacturing by Immatics Infusion of ACTengine® IMA203 TCR - T Product Lymphodepletion * Low dose IL - 2 ** Safety an
Slide 14: ACTengine IMA203 TCR-T Trial in Melanoma
ACTengine® IMA203 TCR - T Trial in Melanoma Heavily Pretreated Patient Population Data cut - off Aug 23, 2024 14 1 See patient flow in appendix. 2 All infused patients; *Cutaneous melanoma patients had a median of 2 prior lines of checkpoints, see appendix; RP2D: recommended phase 2 dose; CPI: Check
Slide 15: Most Frequent Adverse Events of IMA203
15 Data cut - off Aug 23, 2024 • Most frequent adverse events were expected cytopenias (Grade 1 - 4) associated with lymphodepletion in all patients • Mostly mild to moderate cytokine release syndrome (CRS) • 37% (26/70) Grade 1 • 46% (32/70) Grade 2 • 11% (8/70) Grade 3 2 • Infrequent ICANS (6% Gra
Slide 16: Tolerability Profile of IMA203 Across All Dose Levels
Tolerability Profile of IMA203 Across All Dose Levels in Phase 1a/b ll ≥Gra 3 v rs v nts (N=70 1 ) TEAEs by maximum severity for all patients in Phase 1a and Phase 1b (N=70 1 ) Data cut - off Aug 23, 2024 16 ≥ Gra 3 Adverse event ( System organ class , Preferred term) % No. 100.0 70 Patients with an
Slide 17: Best Overall Response for IMA203 in Melanoma
Best Overall Response for IMA203 in Melanoma Objective Responses in Heavily Pretreated Patients in Phase 1b (N=28 # ) Data cut - off Aug 23, 2024 17 ongoi n g # First tumor assessment post infusion pending for two melanoma patients at data - cut; * Maximum change of target lesions and RECIST1.1 resp
Slide 18: Response Over Time of IMA203 in Melanoma
Response Over Time of IMA203 in Melanoma Durable Responses 2 Years+ after Treatment in Heavily Pretreated Patients in Phase 1b (N=28 # ) 18 Ongoing Scans at approximately week 6, month 3 and then every 3 months Data cut - off Aug 23, 2024 # First tumor assessment post infusion pending for two melano
Slide 19: Significant Shift in PFS and OS Between Dose Escalation & Expansion
Significant Shift in PFS and OS Between Dose Escalation & Dose Expansion PFS of 6 Months and OS Not Reached in Melanoma Efficacy Population 19 Progression Free Survival Data cut - off Aug 23, 2024 Overall Survival Overall survival (OS) and progression - free survival (PFS) censored at data - cut; *
Slide 20: IMA203 Phase 1b in Melanoma: Overview of Studies
IMA203 Phase 1b in Melanoma: Overview of Studies PFS and OS Data in 2L+ Melanoma Cohorts mOS (months) mPFS (months) Prior lines of therapies 2L+ melanoma patient population N Phase Drug Product not reached 6.0 4% n=0, 18% n=1, 32% n=2, 29% n=3:, 4% n=4, 11% n=5, 4% n=6 86% received prior CPI (median
Slide 21: Enhanced PFS in Phase 1b Melanoma Patients with Deep Responses
Enhanced PFS in Phase 1b Melanoma Patients with Deep Responses N=26 # 21 • Approx. half of all patients have a deep response (>50% tumor reduction) • This subgroup of patients has highly medically meaningful mPFS of more than 1 year • Patients with <50% tumor reduction (including tumor size increase
Slide 22: Dose Response Relationship
0 5 î 10 5 1 î 10 6 1.5 î 10 6 2 î 10 6 2.5 î 10 6 Cmax (vector copies/μg gDNA) 4 6 8 10 Infused Total (CD8 + Dex + ) IMA203 T cell dose (x10 9 ) 2 1 0 Dose Response Relationship IMA203 T Cell Dose is Associated with Clinical Activity and IMA203 T Cell Exposure (N=65 out of 68*) 22 RP2D cPR (n=23) P
Slide 23: Exposure Response Relationship
Exposure Response Relationship IMA203 T Cell Persistence Over Time and T Cell Exposure is Associated with Clinical Response 23 Rapid T cell engraftment (C max ) in all patients with over two years of persistence Higher C max and persistence in patients treated at higher doses in dose expansion versu
Slide 24: Patient Case: Cutaneous Melanoma
Patient Case A - DL4 - 03 : Cutaneous Melanoma 24 Images courtesy of treating physician (Dr. Martin Wermke, University of Dresden) PET - based Complete Response 15 Months Post Infusion and Ongoing Response at 24 Months 51 - year - old male patient with complete remission according to PET imaging aft
Slide 25: SUPRAME: Registration-enabling Randomized Phase 3 Trial
SUPRAME: Registration - enabling Randomized Phase 3 Trial Trial Design Following Recent Type D Meeting with FDA and SA Meeting with PEI 1 25 ACTengine® IMA203 N=180 Investigator’s choice of selected approved treatments N=1 8 0 Endpoints • Primary Endpoint • PFS • Secondary Endpoints • Safety • ORR +
Slide 26: ACTengine IMA203 Summary of Clinical Data
ACTengine® IMA203 TCR - T Monotherapy Targeting PRAME in Melanoma Summary of Clinical Data Tolerability PFS & OS Biological Data Broad Reach Favorable tolerability profile: mostly mild to moderate CRS; infrequent ICANS (5.7% Gr1, 4.3% Gr2, 4.3% Gr3); no treatment related deaths Anti - Tumor Activity
Slide 27: High Unmet Medical Need in Cutaneous and Uveal Melanoma
27 High Unmet Medical Need in Cutaneous and Uveal Melanoma Clinically and Commercially Attractive Features of IMA203 Uveal Melanoma Cutaneous Melanoma Kim m t r a k - r e f r a c t o r y , CPI/chemotherapy - refractory 2L+ CPI - refractory, BRAF/MEK inhibitor - refractory if BRAF mutation+ 2L+ Patie
Slide 28: IMA203CD8 GEN2 – Leveraging CD8 and CD4 cells
IMA203CD8 GEN2 – IMA203 TCR - T Monotherapy Leveraging CD8 and CD4 cells Differentiated Pharmacology Compared to 1 st - Generation TCR - only Approaches • IMA203CD8 (GEN2) designed to broaden the clinical potential of IMA203 TCR - T monotherapy by adding functional CD4 T cells via co - transduction
Slide 29: IMA203CD8 (GEN2) – Preclinical Assessment of Anti-Tumor Efficacy
IMA203CD8 (GEN2) – Preclinical Assessment of Anti - Tumor Efficacy Functional CD4 T cells Mediate Longer Anti - Tumor Activity than CD8 T cells in vitro 29 1 .0 1 .5 2 .0 CD 8 0.5 0.0 0 50 100 150 200 250 300 350 400 450 Hours after Coculture Tumor fold growth 2 nd addition of tumor cells 3 rd 4 th
Slide 30: IMA203CD8 (GEN2) – Overview of Patient Characteristics
* Patients with at least one available tumor response assessment post infusion; IMA203CD8 DL3: 0.2 - 0.48x10 9 TCR - T cells/m 2 BSA, IMA203CD8 DL4a: 0.481 - 0.8x10 9 TCR - T cells/m 2 BSA, All Comers N=12 Efficacy population* 3 (1, 5) Prior lines of systemic treatment (median, min, max) 50.0 LDH at
Slide 31: Tolerability Data – IMA203CD8 (GEN2)
Tolerability Data – IMA203CD8 (GEN2) 31 % No. ( System organ class , preferred term) 100.0 12 Patients with any adverse event 25.0 3 Adverse events of special interest 25.0 3 Cytokine release syndrome 1 0.0 0 Immune effector cell - associated neurotoxicity syndrome 91.7 11 Blood and lymphatic system
Slide 32: IMA203CD8 (GEN2) – BOR and Response over Time
IMA203CD8 (GEN2) (N=12 # ) – BOR and Response over Time Data cut - off Sep 30, 2023 • 6 out of 7 responses ongoing • 11/12 patients show tumor shrinkage • Deepening of response from SD to PR in two patients (C - DL4a - 01, C - DL4a - 03) • Ongoing durable response 12+ months after infusion Not reach
Slide 33: IMA203CD8 (GEN2): Translational Data Shows Enhanced Pharmacology
IMA203CD8 (GEN2): Translational Data Shows Enhanced Pharmacology IMA203 Phase 1b vs IMA203CD8 (GEN2) Trend towards responses at lower cell dose and higher tumor burden with IMA203CD8 Higher peak expansion (C max ) of IMA203CD8 T cells when normalized to infused dose Higher activation levels in IMA20
Slide 34: Summary of IMA203CD8 Clinical Data and Planned Next Steps
ACTengine® IMA203CD8 (GEN2) TCR - T Monotherapy Targeting PRAME Summary of IMA203CD8 Clinical Data and Planned Next Steps • Enhanced primary and secondary pharmacology when compared to IMA203 • Manageable tolerability (2 DLTs at DL4b, dose escalation ongoing) • Initial clinical activity observed wit
Slide 35: Potential of IMA203 in Additional Solid Cancer Indications
PRAME mRNA expression in IMA203 Phase 1a and Phase 1b responders at RP2D (n=13) PRAME mRNA expression in IMA203CD8 (GEN2) responders (n=7) Potential of IMA203 in Additional Solid Cancer Indications % PRAME - positive patients 1 PRAME target expression distribution (blue histogram) based on TCGA RNAs
Slide 36: Leveraging the Full Breadth of PRAME in Three Steps
36 ACTengine® IMA203 / IMA203CD8 TCR - T Monotherapy Targeting PRAME Leveraging the Full Breath of PRAME in Three Steps Development Strategy Step 1 IMA203 in cutaneous melanoma as first tumor type targeted to enter registration - enabling trial in December 2024 Further dose escalation in melanoma fo
Slide 37: TCER – TCR Bispecifics
TCER® – TCR Bispecifics 37
Slide 38: TCER – Next-generation, Half-Life Extended Bispecifics
TCER® – Immatics’ N xt - generation, Half - Life Extended Bispecifics Proprietary TCER® Format Consisting of Three Distinct Elements 38 High - affinity TCR domains targeting XPRESIDENT® - selected tumor - specific peptide - HLA molecules L o w - a ffi n i t y T cell recruiter against CD3/TCR Fc part
Slide 39: TCER – Next-generation, Half-Life Extended Bispecifics
TCER® – Immatics’ N xt - generation, Half - Life Extended Bispecifics 39 pHLA targeting TCR x High - affinity (single digit nM) TCR targeting XPRESIDENT® - selected tumor - specific peptide - HLA molecules x Broad therapeutic window through XPRESIDENT® - guided affinity maturation (>1000x) 1 x Compl
Slide 40: Potency of Our Proprietary TCR Bispecific Format TCER
Potency of Our Proprietary TCR Bispecific Format TCER® 40 • Seven different TCR Bispecific formats were evaluated with a pHLA targeting TCR and the identical T cell recruiting antibody • TCER® format had higher combination of potency and specificity 2 than six alternative TCR Bispecific format desig
Slide 41: TCER Format Designed for Optimized Efficacy and Safety
TCER® Format Is Designed for Optimized Efficacy and Safety Superior Tumor Control Using a Novel, Low - Affinity Recruiter 41 n = 6 mice/treatment group, n = 10 mice in vehicle group, 2 donors/group Dose : 0 . 025 mg/kg Proprietary, low - affinity T cell recruiting region demonstrates superior tumor
Slide 42: Reduced Recruiter-Mediated Cytokine Release
TCER® Format Is Designed for Optimized Efficacy and Safety Reduced Target - Unrelated Recruiter - Mediated Cytokine Release using a Low - Affinity Recruiter 42 T CE R® Whole blood cytokine release assay N=3 HLA - A*02 - positive donors N=16 cytokines tested, 4 exemplary cytokines shown
Slide 43: Our TCER Portfolio
Our TCER® Portfolio Broad Pipeline of Next - Gen Half - Life Extended TCR Bispecifics 43 T CE R® • PRAME peptide presented by HLA - A*02:01 • Start of clinical trial in Aug 2023, first clinical data expected 2H 2024 IMA402 Potential for addressing different indications and large patient populations
Slide 44: In Vivo Expressed TCER Molecules with Moderna
In Vivo Expressed TCER® Molecules Targeting Cancer - specific pHLA Targets ombining Immatics’ arg t an latforms with o rna’s m N chnology 44 Moderna Delivery of TCER® biologics through mRNA Immatics Proprietary cancer targets & TCR Bispecifics format mRNA - encoded TCER® molecule XPR E SIDENT® targe
Slide 45: TCER IMA401 Targeting MAGEA4/8
TCER® IMA401 Targeting MAGEA4/8 45
Slide 46: Higher Target Density of MAGEA4/8 Peptide
TCER® IMA401 Targeting MAGEA4/8 Higher Target Density of MAGEA4/8 Peptide 46 MAGEA4 protein detection in tumor samples (IHC) 1 MAGEA4/8 target prevalences are based on TCGA and in - house data combined with a XPRESIDENT® - determined target individual MS - based mRNA expression threshold; qPCR - thr
Slide 47: IMA401 Anti-Tumor Activity in vitro
TCER® IMA401 (MAGEA4/8) – Assessment of Anti - Tumor Activity in vitro Patient - Derived Tumor Model 47 NSCLC adenocarcinoma: • Male, Caucasian, age 58, no therapy prior to surgery • Site of origin: lung, differentiation poor • Date of surgery: 1987, Freiburg Medical Center • Volume doubling time: 7
Slide 48: IMA401-101 Phase 1a Dose Escalation Trial Design
48 180 µg 540 µg 1800 µg 2500 µg Key Eligibility Criteria Object iv es Primary: • Determine MTD and/or RP2D Secondary: • Tolerability • Pharmacokinetics • Initial anti - tumor activity • Recurrent and/or refractory solid tumors • HLA - A*02:01 positive • MAGEA4/8 - positive as confirmed by mRNA - b
Slide 49: Baseline Characteristics
Baseline Characteristics Heavily Pre - treated Patients with a Broad Range of Tumor Types 49 1 Efficacy Analysis Set (EAS) prospectively defined in the study protocol: patients who received at least four IMA401 infusions and had at least one post - baseline efficacy assessment or clinical progressio
Slide 50: IMA401 Demonstrates Manageable Tolerability
50 IMA401 Demonstrates Manageable Tolerability in N=35 Patients Most Frequent Related AEs were Lymphopenia, CRS and Neutropenia ≥ Gra 3 All Grades TEAEs, n [%] 26 [74] 32 [91] Any 19 [54] 28 [80] Treatment - related ≥ Gra 3 All Grades Treatment - related AEs 1 , n [%] 11 [31] 12 [34] Lymphopenia 0 1
Slide 51: IMA401 Pharmacokinetics
IMA401 Pharmacokinetics TCER® Format Shows Extended Half - Life in Solid Cancer Patients 1 Half - lifes derived from 2nd PK profiles close to steady - state. Calculated by non - compartmental analysis (NCA) using Phoenix WinNonlin (Certara); Interquartile range (25% - 75% percentile): 13.5 - 22.2 da
Slide 52: Objective Responses are Associated with Target Expression
1 Patients in this analysis had received IMA401 infusions at ≥1 mg and showed MAGEA4/8 target expression above indicated MAGEA4/A8 high qPCR threshold (n=17); PD: Progressive disease; PR: Partial response; cPR: confirmed Partial response; SD: Stable disease. 52 Data cut - off Jul 23, 2024 Objective
Slide 53: IMA401 Tumor Shrinkage in Patients
53 *Patients in this analysis are part of the efficacy analysis set with at least one post - treatment tumor assessment and had received IMA401 infusions at ≥1 mg and showed MAGEA4/8 target expression higher than the MAGEA4/8 qPCR threshold (n=17); Confirmed ORR (cORR): Confirmed objective response
Slide 54: Clinical Activity in Heavily Pre-Treated Cancer Patients
Clinical Activity in Heavily Pre - Treated Cancer Patients 54 CT and MRI scans courtesy of treating physicians (Dr. Manik Chatterjee, University Hospital Wuerzburg and Dr. Max - Felix Häring, Eberhard Karls University Tuebingen); HNSCC: Head and neck squamous cell carcinoma; NET CUP: Neuroendocrine
Slide 55: First-in-human Data of IMA401 Presentation at ESMO
First - in - human Data of IMA401 TCER® Targeting MAGEA4/8 Presentation at ESMO on September 16, 2024 • Tolerability : Most common treatment - related AEs are low - grade CRS, transient lymphopenia and neutropenia • Pharmacokinetics : Median terminal half - life of 16.9 days supporting potential fur
Slide 56: TCER IMA402 Targeting PRAME
TCER® IMA402 Targeting PRAME 56
Slide 57: IMA402 Efficacy Assessment in vitro
TCER® IMA402 Targeting PRAME – Efficacy Assessment in vitro Tumor Cell Killing at Low Physiological PRAME Peptide Levels 57 140 120 100 80 60 40 20 0 ~50 PRAME CpCs 0 140 120 100 80 60 40 20 0 10 - 1 10 0 10 1 10 2 10 3 10 4 10 5 IMA402 [pM] Cytotoxicity [%] Target - negative 0 140 120 100 80 60 40
Slide 58: IMA402 Achieves Durable Tumor Control of Large Tumors in vivo
TCER® IMA402 Achieves Durable Tumor Control of Large Tumors in vivo 58 • Dose - dependent efficacy of IMA402 in cell line - derived in vivo mouse model • Durable shrinkage of large tumors including complete responses over prolonged period • Sufficiently high drug doses are key to achieving desired a
Slide 59: Half-life Extended Format of IMA402
Half - life Extended Format of IMA402 Confers Terminal Half - life of >1 Week 59 pHLA – aFc Assay pHLA – aV L Assay • IMA402 shows a terminal serum half - life of ≈ 8 days in mice • IMA402 will be initially dosed weekly in the clinical trial • Dosing frequency may be adapted based on clinical data I
Slide 60: Phase 1/2 Clinical Trial to Evaluate TCER IMA402
Phase 1/2 Clinical Trial to Evaluate TCER® IMA402 Targeting PRAME First Clinical Data Planned in 2H 2024 60 Phase 1: Dose Escalation Phase 2a: Dose Expansion Adaptive design aimed at accelerating dose escalation • Specific indications plus ongoing basket • Combination therapies • Optional dose/appli
Slide 61: Immatics' Proprietary Target and TCR Discovery Platforms
Immatics’ ro ri tary arg t an Discov ry latforms 61
Slide 62: Our TCR-based Approaches Leverage the Full Target Space
Our TCR - based Approaches Leverage the Full Target Space beyond the Cancer Cell Surface 62 Technology
Slide 63: True Cancer Targets & Matching Right TCRs
True Cancer Targets & Matching Right TCRs Goal to Maximize Anti - Tumor Activity and Minimize Safety Risks of TCR - based Immunotherapies 63 True Targets via XPRESIDENT® technology platform • are naturally presented on tumor tissues as identified by mass - spec • are absent or presented at only low
Slide 64: Pool of Prioritized Targets – XPRESIDENT Target Platform
Technology Pool of 200 Prioritized Targets as Foundation for Future Value Generation XPRESIDENT® Target Platform 64 200 Prioritized Targets Grouped in 3 Target Classes: 1. Well known and characterized parent protein (20%) e.g. MAGE family cancer testis antigens 2. Unknown or poorly characterized par
Slide 65: Potential for Large Patient Populations across Multiple Solid Cancers
Potential for Large Patient Populations across Multiple Solid Cancers 65 Uterine Carcinoma – 97% Uterine Carcinosarcoma – 100% Sarcoma Subtypes – up to 100% Cut. Melanoma – 95% Uveal Melanoma 1 – 89% Ovarian Carcinoma – 84% Squamous NSCLC – 68% TNBC – 63% Small Cell Lung Cancer – 45% Kidney Carcinom
Slide 66: Identification of the Most Relevant Target: MAGEA4/8
Immatics’ Uniqu a ability – Identification of the most Relevant Target Example of MAGEA4/8 Peptide Target 66 1 Copy number per tumor cell (CpC) measured on a paired - sample basis by AbsQuant®, i.e. comparing MAGEA4 vs. MAGEA4/A8 peptide presentation on same sample, 2 Students paired T test p<0.001
Slide 67: Development of the Right TCR – XCEPTOR Technology
Development of the Right TCR – XCEPTOR® Technology TCR Discovery and Engineering for ACT and TCR Bispecifics 67 TCR Bispecifics T cell engaging receptor (TCER®) Adoptive Cell Therapy A C T e n g in e ® ACTallo® • Fast, efficient and highly sensitive discovery of highly specific, natural TCRs • Prote
Slide 68: Optimal Target Selection & TCR Specificity
Optimal Target Selection & TCR Specificity for Minimizing Safety Risks Unique Interplay between Technology Platforms Allows Early De - risking for Clinical Development 68 Target peptide presented on tumor cells Selective killing of tumor cells Target peptide presented on normal cells Of f - t a r ge
Slide 69: Bioinformatics and AI-Platform XCUBE
“ I Is Wh r th Data Is®” Bioinformatics and AI - Platform XCUBE 69 Data Engineering Development of data warehouses & user interfaces Data Science Development of statistical & machine learning models Data Processing Processing of mass - spec & next - gen sequencing data 1 THE RA PE U TIC KNOWLEDGE XP
Slide 70: Robust Intellectual Property Portfolio
Immatics’ obust Int ll ctual ro rty ortfolio Protection Strategy of Key Assets in Major Markets and Beyond 70 Technologies T ar g e ts T CRs T C ER® Th e r ap e u t ic Uses Cell Therapy TCRs with high affinity and specificity profile Differentiated technologies, platforms and assays for Target Resea
Slide 71: ACTengine IMA204 – TCR-T Targeting COL6A3 Exon 6
ACTengine® IMA204 – TCR - T Targeting COL6A3 Exon 6 71
Slide 72: ACTengine IMA204 First-in-Class TCR-T Targeting Tumor Stroma
ACTengine® IMA204 First - in - Class TCR - T Targeting Tumor Stroma Key Features 72 HLA - A*02 - presented peptide derived from COL6A3 exon 6 Naturally and specifically presented on tumors at high target density 1 : 100 - 700 copies/cell Novel tumor stroma target identified and validated by XPRESIDE
Slide 73: IMA204 High Affinity, CD8-independent TCR
ACTengine® IMA204 – High Affinity, CD8 - independent TCR Complete Tumor Eradication in vitro & in vivo 1 by Affinity - enhanced IMA204 TCR CD8 - independent TCR leads to tumor eradication in all mice treated 73 W Si Do ild t ngl ub l y pe e m e m utan u t a n t t T u No mo n - t r ce ran lls o s duc
Slide 74: ACTallo – Our Next-generation Off-the-shelf TCR-T
ACTallo® – Our Next - generation Off - the - shelf TCR - T 74
Slide 75: ACTallo – Immatics' Allogeneic Cell Therapy Approach
ACTallo® – Immatics’ llog n ic ll h ra y roach • Off - the - shelf cell therapy , no need for personalized manufacturing reduced logistics and time to application • Potential for hundreds of doses from one single donor leukapheresis lower cost of goods • Use of healthy donor material provides st
Slide 76: Why γδ T Cells?
Why γδ c lls? γδ T cells Are Well Suited for an Off - the - shelf Cell Therapy Approach 76 γδ T cells x are abundant in the peripheral blood x show intrinsic anti - tumor activity x naturally infiltrate solid tumors & correlate with favorable prognosis x are HLA - independent, thus do not cause graf
Slide 77: Corporate Information & Milestones
Corporate Information & Milestones 77
Slide 78: Experienced Global Leadership Team
Harpreet Singh Chief Executive Officer Co - Founder >20 yrs biotech experience Arnd Christ Chief Financial Officer >20 yrs biotech experience (InflaRx, Medigene, NovImmune, Probiodrug) Carsten Reinhardt Chief Development Officer >20 yrs pharma & biotech experience (Micromet, Roche, Fresenius) Cedrik
Slide 79: Strong, Focused and Highly Integrated Trans-Atlantic Organization
Strong, Focused and Highly Integrated Trans - Atlantic Organization 79 Houston, Texas ~205 FTEs Cell therapy development & manufacturing Munich, Germany ~85 FTEs Various operating functions Tübingen, Germany ~255 FTEs Target & TCR discovery and TCR Bispecifics d ev elopm e nt Corporate FTEs as of Ju
Slide 80: Delivering the Power of T cells to Cancer Patients
Deli v ering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. www.immatics.com